Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?

Annales d'endocrinologie - 1 Oct 2015

Ilhan Muzaffer, Kahraman Ozlem Timirci, Turan Saime, Turgut Seda, Karaman Ozcan, Zeybek Umit, Shukurov Samir, Yaylim Ilhan, Tasan Ertugrul

Abstract excerpt

OBJECTIVES: Genetic alterations explaining the clinical variability of prolactinomas still could not be clarified and dopamine D2 receptor (DRD2) polymorphism is a putative candidate for the variable response to dopaminergic treatment. The present study was conducted to investigate the influence of DRD2 TaqI A polymorphism on initial and follow-up characteristics of prolactinoma. PATIENTS AND METHODS: Seventy-two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Case-Control Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dopamine Agonists

Share to Magnetic Resonance Imaging

Share to Pituitary Neoplasms

Share to Polymorphism, Restriction Fragment Length

Share to Prolactin

Share to Receptors, Dopamine D2

Source

Identifiers

PMID: 26514951
DOI: 10.1016/j.ando.2015.08.005

Genes

DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?PMID 26514951Read ↗

Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.Semantic proximity Read ↗

Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas.Semantic proximity Read ↗

The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas.Semantic proximity Read ↗

Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.Semantic proximity Read ↗

The Role of p16 and MDM2 Gene Polymorphisms in Prolactinoma: MDM2 Gene Polymorphisms May Be Associated with Tumor Shrinkage.Semantic proximity Read ↗

Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomasSemantic proximity Read ↗

Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders.Semantic proximity Read ↗

Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas.Semantic proximity Read ↗

Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia.Semantic proximity Read ↗

Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analysesSemantic proximity Read ↗

The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.Semantic proximity Read ↗

Effect of cyclin [corrected] D1 (CCND1) gene polymorphism on tumor formation and behavior in patients with prolactinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.